Government-Owned Inventions; Availability for Licensing, 43366 [2023-14308]
Download as PDF
<![CDATA[
43366
Federal Register / Vol. 88, No. 129 / Friday, July 7, 2023 / Notices
and Resources Research, National Institutes
of Health, HHS)
Dated: June 30, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–14297 Filed 7–6–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information may be obtained
by communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852 by contacting
Chris Kornak at 240–627–3705 or
chris.kornak@nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished information related to the
invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
Dual-Germline Antibody Engager
Chimeric HIV–1 Immunogens
Description of Technology: Despite
four decades of intensive research, a
safe and effective HIV–1 vaccine
remains elusive due to the extreme
difficulty in eliciting broadly
neutralizing antibodies (bNAbs), which
recognize and block HIV–1 from
entering healthy cells. Only rare natural
HIV–1 envelopes (Envs) promote the
activation and expansion of naı¨ve B
cells expressing unmutated germline
antibodies of various bNAb lineages, but
they typically do so for a single lineage
for the same neutralization site. To
overcome this challenge, NIAID has
designed and characterized two
chimeric HIV–1 Env immunogens
capable of simultaneously engaging
VerDate Sep<11>2014
18:55 Jul 06, 2023
Jkt 259001
multiple germline bNAb lineages. Both
chimeric Env immunogens maintain
native-like folding and engage two
lineages of germline bNAbs directed
against two independent sites of HIV–1
vulnerability.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Immunization: The dual-germline
engager HIV–1 immunogens could be
employed during the priming phase of
an HIV vaccine to trigger multiple bNAb
lineages simultaneously, resulting in a
multi-target protective antibody
response.
• Clinical Treatment: The dualgermline engager HIV–1 immunogens
could serve as an alternative to current
anti-retrovirals or incorporated into
current HIV treatment strategies.
Competitive Advantages:
• Dual-germline engager HIV–1 Env
immunogens are inherently superior to
the currently available single-germline
engagers for eliciting bNAbs.
• The chimeric design could be
expanded to generate HIV–1 Env trimers
with even more germline bNAb
specificities to enable a broader
immunogenic response against HIV.
Inventors: Peng Zhang, Ph.D., Paolo
Lusso, M.D., Ph.D., both of NIAID.
Publications: Publication pending.
Intellectual Property: HHS Reference
No. E–140–2022; US Provisional
Application No. 63/397,789.
Licensing Contact: To license this
technology, please contact Chris Kornak
at 240–627–3705 or chris.kornak@
nih.gov, and reference E–140–2022.
Collaborative Research Opportunity:
The Technology Transfer and
Intellectual Property Office is seeking
parties interested in collaborative
research to further develop this
technology by manufacturing nonMRNA virus-like particles incorporating
dual germline engager HIV–1
immunogens and subsequently testing
immunogenicity in non-human
primates. For collaboration
opportunities, please contact Chris
Kornak; 240–627–3705, chris.kornak@
nih.gov.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2023–14308 Filed 7–6–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Social
Sciences and Population Studies A:
Additional Applications.
Date: July 31, 2023.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Suzanne Ryan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3139,
MSC 7770, Bethesda, MD 20892, (301) 435–
1712, ryansj@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 30, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–14323 Filed 7–6–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
E:\FR\FM\07JYN1.SGM
07JYN1
]]>Agencies
[Federal Register Volume 88, Number 129 (Friday, July 7, 2023)]
[Notices]
[Page 43366]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-14308]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852 by contacting Chris Kornak at 240-
627-3705 or [email protected]. A signed Confidential Disclosure
Agreement will be required to receive copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Dual-Germline Antibody Engager Chimeric HIV-1 Immunogens
Description of Technology: Despite four decades of intensive
research, a safe and effective HIV-1 vaccine remains elusive due to the
extreme difficulty in eliciting broadly neutralizing antibodies
(bNAbs), which recognize and block HIV-1 from entering healthy cells.
Only rare natural HIV-1 envelopes (Envs) promote the activation and
expansion of na[iuml]ve B cells expressing unmutated germline
antibodies of various bNAb lineages, but they typically do so for a
single lineage for the same neutralization site. To overcome this
challenge, NIAID has designed and characterized two chimeric HIV-1 Env
immunogens capable of simultaneously engaging multiple germline bNAb
lineages. Both chimeric Env immunogens maintain native-like folding and
engage two lineages of germline bNAbs directed against two independent
sites of HIV-1 vulnerability.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
Immunization: The dual-germline engager HIV-1 immunogens
could be employed during the priming phase of an HIV vaccine to trigger
multiple bNAb lineages simultaneously, resulting in a multi-target
protective antibody response.
Clinical Treatment: The dual-germline engager HIV-1
immunogens could serve as an alternative to current anti-retrovirals or
incorporated into current HIV treatment strategies.
Competitive Advantages:
Dual-germline engager HIV-1 Env immunogens are inherently
superior to the currently available single-germline engagers for
eliciting bNAbs.
The chimeric design could be expanded to generate HIV-1
Env trimers with even more germline bNAb specificities to enable a
broader immunogenic response against HIV.
Inventors: Peng Zhang, Ph.D., Paolo Lusso, M.D., Ph.D., both of
NIAID.
Publications: Publication pending.
Intellectual Property: HHS Reference No. E-140-2022; US Provisional
Application No. 63/397,789.
Licensing Contact: To license this technology, please contact Chris
Kornak at 240-627-3705 or [email protected], and reference E-140-
2022.
Collaborative Research Opportunity: The Technology Transfer and
Intellectual Property Office is seeking parties interested in
collaborative research to further develop this technology by
manufacturing non-MRNA virus-like particles incorporating dual germline
engager HIV-1 immunogens and subsequently testing immunogenicity in
non-human primates. For collaboration opportunities, please contact
Chris Kornak; 240-627-3705, [email protected].
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-14308 Filed 7-6-23; 8:45 am]
BILLING CODE 4140-01-P
